Sweet Deception: How Mycobacteria Exploit Immune Receptors to Survive

A sugar on mycobacteria binds to the immune receptor dectin-1 on host macrophages, helping the bacteria survive and driving susceptibility to infection.

Written byLaura Tran, PhD
| 2 min read
Image of the lungs against a blue background.
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Successful infection often depends on a pathogen’s ability to evade host immune cell detection through stealthy mechanisms. After a person inhales Mycobacterium tuberculosis (MTB) into their lungs, phagocytic cells such as macrophages engulf it. Although innate pattern recognition receptors (PRRs) on macrophages recognize the bacteria and activate intracellular immune responses, MTB can dodge these defenses to survive and facilitate the development of tuberculosis.

The PRR dectin-1 recognizes β-glucan sugars on the surface of fungal pathogens. While dectin-1 is best known for playing a role in protective antifungal immunity, accumulating evidence also suggests that it contributes to immune responses against other pathogens, such as mycobacteria, although the underlying mechanisms remain incompletely understood.1

This motivated Shota Torigoe, a bacteriologist at the Japan Institute for Health Security, to investigate dectin-1’s function in the context of MTB infections. In a recent study, published in Science Immunology, Torigoe and his colleagues found that a dectin-1 deficiency in mice increased their resistance to MTB infection.2 In addition, the team found that mycobacterial α-glucans can bind to dectin-1; if the mycobacteria lacked this sugar, it had poorer survival rates within mice and human macrophages. Thus, these findings demonstrate that dectin-1–α-glucan interactions promote intracellular bacterial survival.

The researchers first examined the function of dectin-1 during MTB infection in wild type mice and mice genetically deficient in dectin-1. Mice with macrophages lacking dectin-1 exhibited increased resistance to MTB infection, a reduced inflammatory response, and lived longer than their counterparts. Based on these findings, the researchers hypothesized that dectin-1 influenced innate immune responses during infection.

Continue reading below...

Like this story? Sign up for FREE Microbiology updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

To further explore this, the team conducted in vitro experiments focusing on macrophages, which play a central role in tuberculosis pathogenesis. When macrophages gobbled up MTB, higher levels of dectin-1 expression were associated with increased bacterial burden. Rather than being efficiently degraded within phagosomes, MTB persisted. The researchers found that elevated dectin-1 expression disrupted phagosome maturation and suppressed antibacterial autophagy pathways. By modulating these immune processes, mycobacteria were able to enhance their intracellular survival.

Given that mycobacteria do not express β-glucans, the researchers sought to identify the mycobacterial ligand recognized by dectin-1. Through a series of purification and characterization experiments, they discovered that both mouse and human dectin-1 bind to α-glucan. Further experiments showed that mycobacteria lacking α-glucan had significantly reduced survival within both mouse and human macrophages.

Although dectin-1 is traditionally associated with protective immune responses against fungal infections, these findings reveal that its presence can instead facilitate mycobacterial survival. This study highlights one of MTB’s survival mechanisms and advances understanding of host–pathogen interactions during tuberculosis infection. While additional research is needed, these insights may inform future therapeutic strategies targeting this pathway.

  1. Wagener M, et al. Dectin-1-Syk-CARD9 signaling pathway in TB immunity. Front Immunol. 2018;9:225.
  2. Torigoe S, et al. Mycobacterial α-glucans hijack dectin-1 to facilitate intracellular bacterial survival. Sci Immunol. 2026;11:eadw0732.

Related Topics

Meet the Author

  • Laura Tran, PhD

    Laura Tran is an Assistant Editor at The Scientist. She has a background in microbiology. Laura earned her PhD in integrated biomedical sciences from Rush University, studying how circadian rhythms and alcohol impact the gut. While completing her studies, she wrote for the Chicago Council on Science and Technology and participated in ComSciCon Chicago in 2022. In 2023, Laura became a science communication fellow with OMSI, continuing her passion for accessible science storytelling.

    View Full Profile
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas